MediPrint Ophthalmics reveals positive results from phase 2b study of LL-BMT1 contact lens
November 12th 2024The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary end points with no serious adverse events reported in either cohort.